Daniel R. Budman

13.5k total citations · 3 hit papers
165 papers, 10.5k citations indexed

About

Daniel R. Budman is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Daniel R. Budman has authored 165 papers receiving a total of 10.5k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Oncology, 46 papers in Molecular Biology and 31 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Daniel R. Budman's work include Cancer Treatment and Pharmacology (39 papers), Chronic Lymphocytic Leukemia Research (18 papers) and Breast Cancer Treatment Studies (18 papers). Daniel R. Budman is often cited by papers focused on Cancer Treatment and Pharmacology (39 papers), Chronic Lymphocytic Leukemia Research (18 papers) and Breast Cancer Treatment Studies (18 papers). Daniel R. Budman collaborates with scholars based in United States, United Kingdom and China. Daniel R. Budman's co-authors include Willi Kreis, Donald A. Berry, Constance Cirrincione, Hyman B. Muss, Stuart M. Lichtman, Philip Schulman, Steven L. Allen, I. Craig Henderson, Larry Norton and Nicholas Chiorazzi and has published in prestigious journals such as Science, New England Journal of Medicine and JAMA.

In The Last Decade

Daniel R. Budman

162 papers receiving 10.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia

1999 1.9k citations Steven L. Allen, Daniel R. Budman et al. profile →
c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer

1994 779 citations Hyman B. Muss, Ann D. Thor et al. profile →
Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer

2006 518 citations Donald A. Berry, Constance Cirrincione et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel R. Budman United States	46	5.1k	2.7k	2.6k	2.3k	1.9k	165	10.5k
Mansoor N. Saleh United States	53	4.2k 0.8×	1.3k 0.5×	2.3k 0.9×	2.7k 1.2×	1.5k 0.8×	214	10.5k
Apostolia M. Tsimberidou United States	58	5.4k 1.1×	2.5k 0.9×	4.8k 1.8×	3.4k 1.5×	1.6k 0.8×	445	14.5k
Terry L. Smith United States	65	7.7k 1.5×	2.0k 0.7×	2.8k 1.1×	2.9k 1.2×	735 0.4×	154	16.0k
Sjoerd Rodenhuis Netherlands	60	6.0k 1.2×	970 0.4×	3.6k 1.4×	2.3k 1.0×	620 0.3×	253	12.8k
D Maraninchi France	47	3.8k 0.7×	1.0k 0.4×	1.3k 0.5×	1.4k 0.6×	1.4k 0.7×	259	8.5k
Charles Erlichman United States	60	6.0k 1.2×	713 0.3×	5.2k 2.0×	1.8k 0.8×	879 0.5×	313	12.0k
Franco Cavalli Switzerland	43	5.0k 1.0×	2.7k 1.0×	1.5k 0.6×	7.7k 3.4×	902 0.5×	190	11.6k
P. Fumoleau France	61	9.6k 1.9×	889 0.3×	3.3k 1.2×	1.1k 0.5×	1.0k 0.5×	326	14.3k
Gordon Rustin United Kingdom	67	5.3k 1.0×	671 0.3×	4.0k 1.5×	1.1k 0.5×	864 0.5×	245	16.0k
Paul Elson United States	60	4.7k 0.9×	1.1k 0.4×	4.5k 1.7×	868 0.4×	1.5k 0.8×	334	13.4k

Countries citing papers authored by Daniel R. Budman

Since Specialization

Citations

This map shows the geographic impact of Daniel R. Budman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel R. Budman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel R. Budman more than expected).

Fields of papers citing papers by Daniel R. Budman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel R. Budman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel R. Budman. The network helps show where Daniel R. Budman may publish in the future.

Co-authorship network of co-authors of Daniel R. Budman

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel R. Budman. A scholar is included among the top collaborators of Daniel R. Budman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel R. Budman. Daniel R. Budman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barginear, Myra F., Monica Leung, & Daniel R. Budman. (2009). The hedgehog pathway as a therapeutic target for treatment of breast cancer. Breast Cancer Research and Treatment. 116(2). 239–246. 21 indexed citations

DiGiovanna, Michael P., David F. Stern, Susan M. Edgerton, et al.. (2008). Influence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-Positive Breast Cancer: Study 8541 From the Cancer and Leukemia Group B. Journal of Clinical Oncology. 26(14). 2364–2372. 7 indexed citations

Berry, Donald A., Constance Cirrincione, I. Craig Henderson, et al.. (2006). Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer. Obstetrical & Gynecological Survey. 61(9). 584–585. 24 indexed citations

Kreis, Willi, et al.. (2001). Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells. British Journal of Cancer. 85(9). 1403–1411. 25 indexed citations

Kornblith, Alice B., James E. Herndon, Enid Zuckerman, et al.. (2001). Social support as a buffer to the psychological impact of stressful life events in women with breast cancer. Cancer. 91(2). 443–454. 207 indexed citations

Lichtman, Stuart M., Jonathan E. Kolitz, Daniel R. Budman, et al.. (2001). Treatment of Aggressive Non-Hodgkinʼs Lymphoma in Elderly Patients With Thiotepa, Novantrone (Mitoxantrone), Vincristine, Prednisone (TNOP). American Journal of Clinical Oncology. 24(4). 360–362. 10 indexed citations

Kreis, Willi, Daniel R. Budman, & Anthony Calabro. (2000). A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents. Cancer Chemotherapy and Pharmacology. 47(1). 78–82. 18 indexed citations

Budman, Daniel R., et al.. (2000). Synergism of Cytotoxic Effects of Vinorelbine and Paclitaxel in Vitro. Cancer Investigation. 18(8). 695–701. 35 indexed citations

Kreis, Willi, et al.. (1999). Activation of MAP kinase during apoptosis mediated by vinorelbine in MCF-7 cells. 40. 13–14. 3 indexed citations

10.

Budman, Daniel R., et al.. (1999). Synergistic effect of estramustine and [3′-keto-Bmtl]-[Val2]-cyclosporine (PSC 833) on the inhibition of androgen receptor phosphorylation in LNCaP cells. Biochemical Pharmacology. 58(7). 1115–1121. 8 indexed citations

11.

Kreis, Willi, et al.. (1998). Androgen Antagonistic Effect of Estramustine Phosphate (EMP) Metabolites on Wild-Type and Mutated Androgen Receptor. Biochemical Pharmacology. 55(9). 1427–1433. 18 indexed citations

12.

Ozer, Howard, James R. Anderson, B. A. Peterson, et al.. (1994). Combination trial of subcutaneous recombinant α₂b interferon and oral cyclophosphamide in follicular low‐grade non‐Hodgkin's lymphoma. Medical and Pediatric Oncology. 22(4). 228–235. 11 indexed citations

13.

Rybak, Mary Ellen, James R. Anderson, Richard Kaplan, et al.. (1993). Phase II trial of etoposide and cisplatin in patients with refractory and relapsed non‐Hodgkin's lymphoma: Cancer and leukemia group B study 8351. Medical and Pediatric Oncology. 21(6). 441–445. 2 indexed citations

14.

Puccio, Carmelo, Abraham Mittelman, Stuart M. Lichtman, et al.. (1991). A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.. Journal of Clinical Oncology. 9(9). 1562–1569. 73 indexed citations

15.

Lichtman, Stuart M., Daniel R. Budman, Jay L. Bosworth, et al.. (1991). Adjuvant Therapy of Stage II Breast Cancer Treated with CMFVP, Radiation Therapy and VATH Following Lumpectomy A Pilot Trial. American Journal of Clinical Oncology. 14(4). 317–321. 5 indexed citations

16.

Budman, Daniel R., Willi Kreis, Philip Schulman, et al.. (1990). Phase I trial of intravenous vinzolidine (LY 104208) given on a biweekly dosing schedule. Investigational New Drugs. 8(3). 269–274. 2 indexed citations

17.

Rybak, Mary Ellen, et al.. (1990). Phase II trial of etoposide and cis‐diaminodichloro‐platinum in patients with refractory and relapsed Hodgkin's disease: Cancer and leukemia group B (CALGB) study 8353. Medical and Pediatric Oncology. 18(3). 177–180. 2 indexed citations

18.

Budman, Daniel R., Ann H. Korzun, Joseph Aisner, et al.. (1990). A Feasibility Study of Intensive CAF as Outpatient Adjuvant Therapy for Stage II Breast Cancer in a Cooperative Group: CALGB 8443. Cancer Investigation. 8(6). 571–575. 7 indexed citations

19.

Lichtman, Stuart M., et al.. (1989). Testicular malignancy associated with massive inguinal adenopathy and life threatening hemorrhage.. PubMed. 89(8). 482–3. 1 indexed citations

20.

Battisto, Jack R., Daniel R. Budman, & Robert Freedman. (1971). SPECIFICITY OF FIXATION LOCI FOR HOMOCYTOTROPIC ANTIBODIES. The Journal of Experimental Medicine. 134(2). 381–394. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact